Amedisys Stock Performance
AMED Stock | USD 92.46 0.17 0.18% |
The firm shows a Beta (market volatility) of -0.19, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Amedisys are expected to decrease at a much lower rate. During the bear market, Amedisys is likely to outperform the market. Amedisys has an expected return of -0.0445%. Please make sure to confirm Amedisys potential upside, day median price, and the relationship between the total risk alpha and accumulation distribution , to decide if Amedisys performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Low | High |
Very Weak
Over the last 90 days Amedisys has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound technical and fundamental indicators, Amedisys is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.18 | Year To Date Return (2.64) | Ten Year Return 527.7 | All Time Return 1.7 K |
Last Split Factor 4:3 | Last Split Date 2006-12-05 |
1 | Amedisys Research Coverage Started at StockNews.com - MarketBeat | 01/18/2024 |
2 | Acquisition by Denise Bohnert of 5518 shares of Amedisys subject to Rule 16b-3 | 02/16/2024 |
3 | Disposition of 1415 shares by Denise Bohnert of Amedisys at 93.69 subject to Rule 16b-3 | 02/20/2024 |
4 | Brokerages Set Amedisys, Inc. PT at 103.22 | 02/26/2024 |
5 | UnitedHealth slumps on DoJ antitrust probe and ransomware hacker reports | 02/28/2024 |
6 | Bank of Nova Scotia Acquires Shares of 285,557 Amedisys, Inc. | 02/29/2024 |
7 | Amedisys Earns Buy Rating from Analysts at StockNews.com - MarketBeat | 03/06/2024 |
8 | Hudson Bay Capital Management LP Has 15.55 Million Stock Position in Amedisys, Inc. - MarketBeat | 03/13/2024 |
9 | UPDATE 1-Oregons health authority reviewing UnitedHealths acquisition of Amedisys | 03/19/2024 |
10 | How Amedisys Stock Stands Out in a Strong Industry | 03/20/2024 |
11 | RBC raises Amedisys stock PT to 100 on AMED deal completion confidence | 03/25/2024 |
Begin Period Cash Flow | 61.7 M |
Amedisys |
Amedisys Relative Risk vs. Return Landscape
If you would invest 9,506 in Amedisys on December 29, 2023 and sell it today you would lose (260.00) from holding Amedisys or give up 2.74% of portfolio value over 90 days. Amedisys is currently does not generate positive expected returns and assumes 0.4343% risk (volatility on return distribution) over the 90 days horizon. In different words, 3% of stocks are less volatile than Amedisys, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Amedisys Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Amedisys' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Amedisys, and traders can use it to determine the average amount a Amedisys' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1025
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | AMED |
Estimated Market Risk
0.43 actual daily | 3 97% of assets are more volatile |
Expected Return
-0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Amedisys is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amedisys by adding Amedisys to a well-diversified portfolio.
Amedisys Fundamentals Growth
Amedisys Stock prices reflect investors' perceptions of the future prospects and financial health of Amedisys, and Amedisys fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Amedisys Stock performance.
Return On Equity | -0.0098 | ||||
Return On Asset | 0.0598 | ||||
Current Valuation | 3.38 B | ||||
Shares Outstanding | 32.67 M | ||||
Price To Earning | 15.03 X | ||||
Price To Book | 2.83 X | ||||
Price To Sales | 1.35 X | ||||
Revenue | 2.24 B | ||||
Gross Profit | 453.98 M | ||||
EBITDA | 216.91 M | ||||
Net Income | (9.75 M) | ||||
Cash Per Share | 0.55 X | ||||
Debt To Equity | 0.53 % | ||||
Current Ratio | 1.06 X | ||||
Cash Flow From Operations | 137.19 M | ||||
Earnings Per Share | (0.30) X | ||||
Total Asset | 2.06 B | ||||
Retained Earnings | 747.92 M | ||||
Current Asset | 175.26 M | ||||
About Amedisys Performance
To evaluate Amedisys Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Amedisys generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Amedisys Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Amedisys market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Amedisys's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.12 | 0.13 | |
Return On Assets | (0) | (0) | |
Return On Equity | (0.01) | (0.01) |
Things to note about Amedisys performance evaluation
Checking the ongoing alerts about Amedisys for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Amedisys help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Amedisys generated a negative expected return over the last 90 days | |
The company reported the previous year's revenue of 2.24 B. Net Loss for the year was (9.75 M) with profit before overhead, payroll, taxes, and interest of 453.98 M. | |
Over 96.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from investing.com: RBC raises Amedisys stock PT to 100 on AMED deal completion confidence |
- Analyzing Amedisys' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Amedisys' stock is overvalued or undervalued compared to its peers.
- Examining Amedisys' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Amedisys' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Amedisys' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Amedisys' stock. These opinions can provide insight into Amedisys' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amedisys. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Amedisys Stock analysis
When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.40) | Earnings Share (0.30) | Revenue Per Share 68.603 | Quarterly Revenue Growth 0.016 | Return On Assets 0.0598 |
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.